Mode
Text Size
Log in / Sign up

Review synthesizes rTMS and tDCS efficacy for neuropathic orofacial pain management

Review synthesizes rTMS and tDCS efficacy for neuropathic orofacial pain management
Photo by Ben Maffin / Unsplash
Key Takeaway
Note that rTMS reduces neuropathic orofacial pain by 30-45%, but evidence is limited by small samples.

This mini-review examines the application of Repetitive Transcranial Magnetic Stimulation (rTMS) and Transcranial Direct Current Stimulation (tDCS) for patients with neuropathic orofacial pain. The scope encompasses various stimulation parameters and locations, though specific study populations and sample sizes are not reported. The review synthesizes qualitative conclusions regarding pain reduction and treatment response patterns rather than providing pooled effect sizes from a meta-analysis.

The authors highlight that high-frequency rTMS targeting the primary motor cortex achieves pain reductions of 30% to 45% for trigeminal and postherpetic neuralgia. Furthermore, stimulation of non-somatotopic hand motor cortex areas produces analgesic effects comparable to facial targets. The review suggests that patients presenting with pure paroxysmal pain may demonstrate a more robust response compared to those with persistent pain, although specific numerical data for these comparisons are not reported.

Significant limitations identified by the authors include small sample sizes and the use of heterogeneous protocols across the included literature. Safety data, such as adverse events or tolerability, were not reported in the source material. Consequently, the authors note that future research should prioritize phenotype-stratified trials to define optimal stimulation parameters and explore synergies with pharmacotherapy. Given the current evidence is limited, clinicians should interpret these findings with restraint until more robust data emerges.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Neuropathic orofacial pain (NOP) can seriously affect the quality of life of patients. Due to the concentration of pain in the central area of the craniofacial region, it is not only highly invasive but also easily distracts the patient's attention, resulting in its destructive nature far exceeding that of distal limb pain. As emerging non-invasive therapies, Repetitive Transcranial Magnetic Stimulation (rTMS) and Transcranial Direct Current Stimulation (tDCS) are bringing hope for the treatment of NOP. This brief review summarizes existing evidence on their efficacy, highlighting that pain phenotype may be a key determinant of treatment response and warrants further investigation. High-frequency (10–20 Hz) rTMS over the primary motor cortex (M1) reduces trigeminal and postherpetic neuralgia pain by 30%–45%, with effects lasting weeks to months. Non-somatotopic hand M1 stimulation appears to produce comparable facial analgesia via descending pain pathways. For tDCS, preliminary evidence suggests pure paroxysmal pain may respond more robustly than persistent pain, implicating central sensitization as a potential negative predictor. Current evidence is limited by small samples and heterogeneous protocols. Future research should prioritize phenotype-stratified trials, optimal parameters, and synergy with pharmacotherapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.